WO1996022019A1 - Composition alimentaire de traitement de l'ascite chez l'animal domestique - Google Patents

Composition alimentaire de traitement de l'ascite chez l'animal domestique Download PDF

Info

Publication number
WO1996022019A1
WO1996022019A1 PCT/US1996/000908 US9600908W WO9622019A1 WO 1996022019 A1 WO1996022019 A1 WO 1996022019A1 US 9600908 W US9600908 W US 9600908W WO 9622019 A1 WO9622019 A1 WO 9622019A1
Authority
WO
WIPO (PCT)
Prior art keywords
gms
composition
metabolic precursors
precursors
animals
Prior art date
Application number
PCT/US1996/000908
Other languages
English (en)
Inventor
Francis J. Carniglia
Original Assignee
Carniglia Francis J
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carniglia Francis J filed Critical Carniglia Francis J
Priority to AU47045/96A priority Critical patent/AU4704596A/en
Publication of WO1996022019A1 publication Critical patent/WO1996022019A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins

Definitions

  • the present invention relates generally to a composition of matter and method for preventing ascites in chickens and physiological stress in pigs, turkeys and other animals. More particularly, the invention provides a composition of matter and method for reducing the number of intracellular free radicals which are incrementally increasing prior to the onset of the visual symptoms of ascites and stress.
  • cardiopulmonary performance cannot keep pace with the demands of the rapid body growth which results from highly selective production practices.
  • the cardiopulmonary system fails both to provide an adequate blood level of oxygen and to deliver a sufficient volume of blood to muscle cells to insure normal intracellular oxygen levels.
  • the resulting hypoxia is characterized by increased production of intracellular free radicals which damage the cell membrane and escape into the blood stream giving rise to the pathologies described above.
  • an object of the invention to provide a composition of matter which prevents ascites in highly selected chickens and stress in pigs, turkeys and other highly selected animals.
  • the present invention meets the above-stated objects by providing a composition of matter which includes anti-oxidants and metabolic precursors of glutathione, metabolic precursors of electron carriers present in the intracellular respiratory chain, metabolic precursors of intracellular respiratory enzymes, a pulmonary vasodilator; precursors for cell membrane constituents, and a blood viscosity modifier.
  • the anti-oxidants comprise vitamin C, vitamin E, and beta carotene
  • the metabolic precursors of glutathione comprise l-glycine, l-cysteine and l-glutamic acid.
  • the electron carriers are the ubiquinones, and the metabolic precursor of this family of electron carriers is l-phenylaianine.
  • the metabolic precursors of intracellular respiratory enzymes include thiamine, riboflavin and nicotinamide, and the pulmonary vasodilator is I- arginine.
  • the metabolic precursors of cell membrane constituents are inositol and dicalcium phosphate, and the blood viscosity modifier is ovalbumin.
  • the present invention also encompasses a composition of matter including several of the constituents mentioned above along with additional components which increase the intracellular level of adenosine triphosphate (hereinafter ATP).
  • the composition of matter includes anti-oxidants and metabolic precursors of glutathione, metabolic precursors of electron carriers present in the intracellular respiratory chain, metabolic precursors of intracellular respiratory enzymes, a pulmonary vasodilator, precursors for cell membrane constituents, amino acids selected from the group of amino acids which are the metabolic precursors of ATP, and choline chloride, magnesium oxide and a pentose sugar.
  • the anti-oxidants, metabolic precursors of glutathione and the metabolic precursor of the ubiquinone family of electron carriers are the same as those set forth above.
  • the metabolic precursors of intracellular respiratory enzymes, the pulmonary vasodilator, and the metabolic precursors of cell membrane constituents are also identical to those described in connection with the first composition of matter.
  • the amino acids are d/l-methionine, l-aspartic acid; I- tryptophan, l-histadine, and l-proline, and the pentose sugar is ribose.
  • the present invention provides a method for preventing ascites in chickens and stress in pigs, turkeys and other highly selected animals which includes the steps of mixing either of the above-described compositions with conventional feed to provide about a 1.5 % wtJwt. mixture of the composition and the feed, and feeding the animals a weight of the mixture corresponding to their normal daily feed ration.
  • the method provides a self- adjusting dosage level of the compositions, since as the animal eat more as they grow older, the amount of the composition ingested each day on a weight basis also increases.
  • the anti-oxidants comprise vitamin C, vitamin E, and beta carotene.
  • Ascorbic acid is probably the most powerful physiological detoxicant known. For example, dogs given saturation doses of ascorbic acid followed by a lethal dose of carbon tetrachloride (a severe liver poison) survived. Dogs that did not receive ascorbic acid before the dose of carbon tetrachloride all died. Further, ascorbic acid is a liver sparer which allows this organ to withstand significant stress. This is important, since the liver of highly selected animals is subject to severe damage in both ascites and stress. Most importantly, ascorbic acid is a potent anti-oxidant, which is known to have a positive effect in reducing the level of intracellular free radicals typically accompanying hypoxia.
  • Vitamin C is also involved in the regeneration of vitamin E, another anti-oxidant known to reduce the level of intracellular levels of free radicals.
  • vitamin E plays an important role in maintaining the integrity of the cell wall. This is particularly important in the prophylaxis and prevention of ascites and stress, since damage to the cell wall, particularly the muscle cell wall, is prevalent in both of these conditions.
  • the final anti-oxidant included in the composition is betacarotene. Not only does this anti- oxidant metabolize intracellular free radicals, but also it is a precursor of vitamin A. This vitamin is known to maintain the health of the mucus membranes in the respiratory track and other organ systems. This additional function of betacarotene is a significant preventative and prophylactic in the prevention of ascites and stress, since damage to the mucus membrane often accompanies both of these diseases.
  • glutathione peroxidase Three amino acids, l-glycine, l-cysteine, and l-glutamic acid are provided by the composition as the metabolic precursors of the anti-oxidant enzyme glutathione peroxidase.
  • glutathione is crucial to the metabolism of free radicals to less harmful compounds.
  • glutathione is the cell's main defense against damage from elevated levels of free radicals.
  • the amino acid l-phenylalinine is included in the composition since it is required in the production of the ubiquinones.
  • the ubiquinones are a family of electron carriers forming part of the intracellular respiratory chain and, in particular, involved in respiratory redox reactions. Accordingly, the ubiquinones and their metabolic precursor l-phenylalinine are important for the proper oxidation of intracellular free radicals.
  • Thamine, riboflavin and niacinamide are included in the formula since they are the metabolic precursors for five intracellular enzymes that are involved in cellular respiration.
  • Thamine is a precursor of cocarboxylase
  • niacinamide is a precursor of coenzyme-1 and coenzyme-2
  • riboflavin is required for the formation of flavin mononucleotide and flavin adenine dinucleotide.
  • These enzymes function to encourage more favorable oxygen interchange between the blood and the intracellular environment and to encourage full utilization of the oxygen that is transported into the cells. Accordingly, these enzymes and their metabolic precursors serve to alleviate hypoxia and reduce the level of intracellular free radicals.
  • the composition includes constituents which serve to maintain integrity of the cell membrane.
  • the composition includes inositol which unites with phosphate to produce phospholipids, known as polyphosphoinositidies found in almost all cell membranes. Dicalcium phosphate is also included in the composition to provide a source of the phosphate ion required for combination with inositol to form the phospholipids.
  • the composition also includes ovalbumin since this compound must be present in adequate amounts within the blood plasma to ensure proper blood viscosity. By maintaining proper viscosity, the resistance to blood flow is reduced, thus increasing the efficiency of oxygen transport the cells. In particular, ovalbumin maintains proper fluid levels within the vascular system and prevents fluid from leaving the blood vessels and seeping into the surrounding tissues.
  • Ovalbumin also has the additional advantage of providing a secondary source of the amino acids glycine, cystein and glutamic acid which, as discussed above, are the metabolic precursors of the anti-oxidant glutathione. Ovalbumin is also a secondary source of the amino acid l-arginine which, as discussed further below, is required for proper pulmonary vasodilation.
  • the final two constituents of the composition are dried beet molasses and a primary source of l-arginine.
  • the dried beet molasses provides a tertiary source for the metabolic precursors of glutathione, and in the preferred embodiment of the invention is Sweet 45 Dried Beet Molasses.
  • the amino acid I- arginine is converted to l-citrulline in the enzymatic production of nitric oxide by pulmonary endothelial nitric oxide synthase. Once produced, nitric oxide defuses to the adjacent vascular smooth muscle to mediate pulmonary vasodilation. Vasodilation reduces pulmonary hypertension and congestion and also reduces the workload on the right ventricle of the heart. Both of these effects are important in reducing the congestive heart failure which typically accompanies ascites and stress.
  • Example 1 The most preferred embodiment of the composition taught by the first aspect of the invention is set forth below in Example 1.
  • the second aspect of the invention relates to a composition of matter which includes many of the compounds discussed above in combination with compounds required for increasing the intracellular levels of ATP.
  • the composition includes inositol, dicalcium phosphate, l-arginine, ascorbin acid, l-phenylalinine, l-glycine, cysteine, l-glutamic acid, beta carotene, thamine, riboflavin, niacinamide and vitamin E. All of these compounds are also contained in the first composition described above and their function in the present composition is identical.
  • the second composition of matter taught by the invention includes the amino acids d/lmethionine, l-aspartic acid, histidine, l-proline and l-tryptophan. These amino acids along with l-glycine mentioned above are known to play a critical role in increasing intracellular levels of ATP.
  • the composition includes choline chloride, magnesium oxide and the pentose sugar D-ribose. These compounds are also essential for increasing the intracellular production of ATP. Increasing intracellular ATP levels enhances the efficacy of the composition because an overall weight increase in the treated animals results but particularly because an increase in heart weight results, which is essential for preventing the congestive heart failure that typically accompanies both ascites and stress.
  • compositions including components for increasing the intracellular level of ATP are set forth below in Example 2.
  • the invention provides a method for preventing ascites and stress in highly selected animals.
  • either one of the compositions described above are mixed with conventional feed to form a 1.5% wt./wt. mixture of the composition and feed.
  • the animal is then given its normal daily feed ration.
  • the dosage of the composition is self-reguiating, since the animal will ingest more of the composition on a weight basis as the daily feed ration is increased with the animal's age.
  • the mixture may be formulated on the basis of 1 ,000 kilograms (2200 lbs.) of feed with the addition of 15 kilograms (33 lbs.) of either one of the compositions set forth in Examples 1 and 2.
  • the amount of composition ingested daily by, for example, a broiler chicken increases as the animal grows older. Table 1

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composition de substances destinée à prévenir les ascites et le stress chez des animaux objet d'une sélection poussée. Ladite composition comporte, d'une part, des ingrédients servant à réduire les niveaux intercellulaires des radicaux libres et à maintenir l'intégrité de la membrane cellulaire et, d'autre part, consiste en un mélange de substances comprenant les ingrédients suscités associés à des ingrédients élevant les niveaux intracellulaires d'ATP. L'invention concerne également un procédé de traitement d'animaux objet d'une sélection poussée par ladite composition.
PCT/US1996/000908 1995-01-20 1996-01-18 Composition alimentaire de traitement de l'ascite chez l'animal domestique WO1996022019A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU47045/96A AU4704596A (en) 1995-01-20 1996-01-18 Diet compositions to treat ascites in domestic animals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37562895A 1995-01-20 1995-01-20
US08/375,628 1995-01-20

Publications (1)

Publication Number Publication Date
WO1996022019A1 true WO1996022019A1 (fr) 1996-07-25

Family

ID=23481646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/000908 WO1996022019A1 (fr) 1995-01-20 1996-01-18 Composition alimentaire de traitement de l'ascite chez l'animal domestique

Country Status (2)

Country Link
AU (1) AU4704596A (fr)
WO (1) WO1996022019A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0797929A1 (fr) * 1996-03-28 1997-10-01 Kohjin Co., Ltd. Aliment pour animaux pour réduire le stress
WO2010096689A1 (fr) * 2009-02-20 2010-08-26 Bioenergy, Inc. Compositions et procédés pour alimenter des volailles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871718A (en) * 1987-12-29 1989-10-03 Raymond A. Roncari Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WINDHOLTZ et al., "The Merck Index", 10th Edition, Published 1983, by MERCK, DOHME & SHARPE, (RAHWAY, NJ), page 1451, Abstract # 9904. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0797929A1 (fr) * 1996-03-28 1997-10-01 Kohjin Co., Ltd. Aliment pour animaux pour réduire le stress
US5968810A (en) * 1996-03-28 1999-10-19 Kohjin Co., Ltd. Stress-relieving feed
WO2010096689A1 (fr) * 2009-02-20 2010-08-26 Bioenergy, Inc. Compositions et procédés pour alimenter des volailles
US20110021446A1 (en) * 2009-02-20 2011-01-27 St Cyr John A Compositions and methods for feeding poultry
CN102639003A (zh) * 2009-02-20 2012-08-15 生物能公司 喂养家禽的组合物和方法
JP2012518413A (ja) * 2009-02-20 2012-08-16 バイオエナジー インコーポレイティド 家禽に肥料を与えるための組成物及び方法
US8741854B2 (en) * 2009-02-20 2014-06-03 Bioenergy, Inc. Compositions and methods for feeding poultry

Also Published As

Publication number Publication date
AU4704596A (en) 1996-08-07

Similar Documents

Publication Publication Date Title
US5254572A (en) Method and composition for supplementing vitamin B6 where the PN-PLP pathway is disturbed
Kabu et al. Biological effects of boron
AP387A (en) Therapeutical uses of L-methionine and compositions thereof.
Svoboda et al. Iron deficiency in suckling piglets: etiology, clinical aspects and diagnosis
Pesti et al. Sulfur amino acid and methyl donor status of corn-soy diets fed to starting broiler chicks and turkey poults
Roediger et al. New views on the pathogenesis of kwashiorkor: methionine and other amino acids
EP0680945A2 (fr) Amino acide, carnithine et magnésium supplémentation
Riordan et al. The effects of a primary nutritional deficiency (Vitamin B study)
LEWIS et al. Dietary protein and the toxicity of sodium selenite in the white rat
US4528295A (en) Composition and method for reducing blood acetaldehyde levels
EP0270026A2 (fr) Compositions pharmaceutiques contenant de la vitamine B6
Himwich et al. Studies in the Physiology of Vitamins: XVII. The Effect of Thyroid Administration upon the Anorexia Characteristic of Lack of Undifferentiated Vitamin B
KR100868592B1 (ko) 크레아틴 에스터 전영양소 화합물과 제형
Zieve et al. Effect of magnesium deficiency on growth response to thiamine of thiamine-deficient rats
WO1996022019A1 (fr) Composition alimentaire de traitement de l'ascite chez l'animal domestique
Leverve Metabolic and nutritional consequences of chronic hypoxia
Omole et al. Effect of copper on growth and serum constituents of immunized and non-immunized rabbits infected with Trypanosoma bracei
Klavins et al. Body iron levels and hematologic findings during excess methionine feeding
Bunk et al. Evidence for an impairment in the conversion of methionine to cysteine in the selenium-deficient chick
Kornberg et al. The effect of L. casei factor (" folic acid") on blood regeneration following hemorrhage in rats
Chen et al. Responses of broilers at moderate or high temperatures to dietary arginine: lysine ratio and source of supplemental methionine activity
EP0655245A2 (fr) Compositions et leur utilisation pour retarder le processus de vieillissement
Denli et al. Effects of vitamin A supplementary in the feed to reduce toxic effects of aflatoxin B1 on Japanese quails (Coturnix coturnix Japonica)
Khajali et al. Fine-tuning low-protein diets through vitamin E supplementation to avoid ascites in broiler chickens
El-kelawy Effects of L-carnitine on production performance, blood parameters, lipid metabolism and antioxidative properties of broiler chicks.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU BB BG BR CA CH CN CZ EE FI GE HU IS JP KG KP KR KZ LK LR LT LV MD MG MK MN MX NO NZ PL PT RO RU SG SI SK TR TT UA UZ VN AZ BY KG KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase